BioMarin Pharmaceutical Inc. (BMRN) Lifted to “Buy” at Zacks Investment Research
The Cerbat Gem | December 28, 2016
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage currently has a $95.00 price target on the stock. Zacks Investment Research’s target price points to a potential upside of 11.66% from the company’s previous close.